Simpson Thacher & Bartlett and Fangda Partners are advising Chinese fintech firm Ant Group on its planned $30 billion initial public offering in Hong Kong and Shanghai, with Freshfields Bruckhaus Deringer and King & Wood Mallesons counselling the joint sponsors.
Simpson Thacher & Bartlett and Anderson Mori & Tomotsune have represented Blackstone in its 242 billion yen ($2.3 billion) acquisition of Takeda Consumer Healthcare, which turned to Nishimura & Asahi for advice.
Khaitan & Co. and Shardul Amarchand Mangaldas have advised Mindspace Business Parks on its $676 million IPO, with Sidley Austin representing the lead managers.
Khaitan & Co and Cyril Amarchand Mangaldas are advising Indian drugmaker Gland Pharma on its planned $780 million IPO, with Herbert Smith Freehills and S&R Associates acting for the bookrunners and lead managers.
Clifford Chance has advised AXA Investment Managers on the $368 million acquisition of ESR Kuki Distribution Centre in Japan from Redwood Japan Logistics Fund II (RJLF II). ESR was advised by White & Case
Baker McKenzie and Farooq & Associates have advised Reliance Bangladesh LNG & Power on its $642 million financing of a 718 MW gas-fired thermal power generation project in the South Asian country, with Clifford Chance and Dr. Kamal Hussain & Associates representing the lenders.
Davis Polk & Wardwell and Jia Yuan Law Offices have advised Chinese clinical trial and research firm Hangzhou Tigermed Consulting on its $1.38 billion Hong Kong IPO, with Freshfields Bruckhaus Deringer and Zhong Lun Law Firm representing the sponsors.
Tian Yuan Law firm and Commerce & Finance Law Offices have led on two new health sector initial public offerings of Hygeia Healthcare and Hepalink Pharma in Hong Kong. They’ve advised the issuers and joint sponsors respectively in both deals.